Dr. Bernard Collins Is Appointed to the Board of Directors of Signum Surgical

Companies in the Global Vaccine Delivery Devices Market Expedite Product Innovations to Stay at Forefront in the Market in the COVID-19 Pandemic

Fact.MR has recently compiled a report, which reveals that the vaccine delivery devices market globally is projected to reflect an impressive CAGR over the forecast period, 2017 – 2022.

Sirtex Medical and BlackSwan Vascular Report 1st Patient Enrolled in Pivotal LAVA Study

The LAVA Study, which stands for Liquid Embolization of Arterial Hemorrhages in Peripheral Vasculature, is a prospective, multicenter single-arm study of 113 subjects at 20 investigational sites in the U.S.

April 7, 2021

Dr. Bernard Collins is a leading expert in the medical technology sector and serves on the Board of Directors of several US and Irish life-science companies including, CroíValve, Aerogen, Atlantic Therapeutics, and Vivasure Medical.

A former Vice President of International Operations for Boston Scientific, where he served for 10 years, Dr. Collins has held a number of senior executive positions in international life-science companies during his career, including at Baxter Healthcare.

Jeff Grainger, Chairman of Signum Surgical, commented: “We are delighted to welcome Bernard to the Board. As we continue to progress our regulatory and clinical programs, Bernard brings a wealth of commercial experience and technical expertise at an important time for the company. We look forward to his contribution.”

Dr. Bernard Collins, Non-Executive Director of Signum Surgical, commented: “I’m excited to join the Board of Signum Surgical and look forward to helping the team accelerate its regulatory and commercial objectives. I believe in Signum Surgical’s innovative BioHealx technology as an effective and viable treatment option for physicians, which has the potential to transform the lives of patients suffering from an anal fistula.”

Headquartered in Galway, Signum Surgical is focused on developing minimally invasive technologies to treat colorectal diseases, principally a condition known as anal fistula. This painful, and often recurring colorectal condition, which severely affects patients’ quality of life, involves the infection of an internal gland. Affecting one in 5,000 people worldwide1, patients and their physicians are dissatisfied with the efficacy of current treatment options, which are rarely successful, and can leave patients suffering with ongoing infections which require repeat procedures.

Developed in collaboration with expert colorectal surgeons, Signum Surgical’s proprietary BioHealxTM technology, which enables surgeons to treat anal fistula with a minimally invasive outpatient procedure, features a single use, bioabsorbable, implant that is designed to help seal the fistula tract and dissolve in the body after treatment. The single-operation approach is designed to promote healing, prevent reinfection, and protect patient continence.

 

spot_img

DON'T MISS

Related Articles